Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial
Authors:
Top Cited Papers
Open Access
- 26 June 2023
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 14 (1) , 1-12
Abstract
Background and aims: The main causes of death in patients with severe Coronavirus disease-2019 (COVID-19) are acute respiratory distress syndrome (ARDS) and multiorgan failure caused by a severe inflammatory cascade. Novel treatment strategies, such as stem-cell-based therapy and their derivatives can be used to relieve inflammation in these cases. In this study, we aimed to evaluate the safety and efficacy of therapy using mesenchymal stromal cells (MSCs) and their derived extracellular vesicles in COVID-19 patients.Materials and methods: COVID-19 patients with ARDS were included in this study and allocated into two study and control groups using block randomization. While all patients received recommended treatment based on guidelines from the national advisory committee for COVID-19 pandemic, the two intervention groups received two consecutive injections of MSCs (100 × 106cells) or one dose of MSCs (100 × 106cells) followed by one dose of MSC-derived extracellular vesicles (EVs). Patients were assessed for safety and efficacy by evaluating clinical symptoms, laboratory parameters, and inflammatory markers at baseline and 48 h after the second intervention.Results: A total number of 43 patients (the MSC alone group = 11, MSC plus EV group = 8, and control group = 24) were included in the final analysis. Mortality was reported in three patients in the MSC alone group (RR: 0.49; 95% CI 0.14–1.11;P = 0.08); zero patient in the MSC plus EV group (RR: 0.08; 95% CI 0.005–1.26;P = 0.07) and eight patients in the control group. MSC infusion was associated with a decrease in inflammatory cytokines such as IL-6 (P = 0.015), TNF-α (P = 0.034), IFN-γ (P = 0.024), and CRP (P = 0.041).Conclusion: MSCs and their extracellular vesicles can significantly reduce the serum levels of inflammatory markers in COVID-19 patients, with no serious adverse events.Trial registrationIRCT, IRCT registration number: IRCT20200217046526N2. Registered 13th April 2020,http://www.irct.ir/trial/47073.Keywords
Funding Information
- Cell Tech Pharmed
- Royesh Venture Capital
This publication has 82 references indexed in Scilit:
- WHO Declares COVID-19 a Pandemic2020
- Rapid Progression to Acute Respiratory Distress Syndrome: Review of Current Understanding of Critical Illness from Coronavirus Disease 2019 (COVID-19) InfectionAnnals of the Academy of Medicine, Singapore, 2020
- A novel coronavirus outbreak of global health concernThe Lancet, 2020
- Unintended consequences of evolution of the Common Terminology Criteria for Adverse EventsPediatric Blood & Cancer, 2019
- Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelinesJournal of Extracellular Vesicles, 2018
- The state-of-play and future of antibody therapeuticsAdvanced Drug Delivery Reviews, 2017
- Future of Haemophilia Research in IndiaIndian Journal of Hematology and Blood Transfusion, 2017
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Acute respiratory distress syndrome: new definition, current and future therapeutic options2013
- The safety and side effects of monoclonal antibodiesNature Reviews Drug Discovery, 2010